H&H Group's revenue from adult nutrition and care products increased significantly
On April 12, H&H Group released its financial report that the company's revenue in 2023 will be 13.926 billion yuan, a year-on-year increase of 9.01%, and its net profit will be 582 million yuan, a year-on-year decrease of 4.89%.
In terms of business, H&H Group's revenue from adult nutrition and care products, infant nutrition and care products, and pet nutrition and care products was 6.145 billion yuan, 5.908 billion yuan, and 1.874 billion yuan respectively, with year-on-year changes of 34.1%, -11.7%, and 18.2% respectively. In terms of products, the revenue of infant formula milk powder was 4.398 billion yuan.
In 2023, H&H Group's adult nutrition and care products segment revenue in the Chinese market increased by 37.4% year-on-year, accounting for 66% of the Group's total revenue of this business segment, with the growth mainly driven by consumer demand and the Group's innovative categories. The decline in infant formula revenue was mainly due to systemic challenges in the industry and intensified competition such as reducing the inventory of old national standard products during the transition to the new national standard.
H&H Group said that the company has achieved the key strategic goals set in 2023, including driving the growth of high-margin nutritional supplement categories, maintaining solid profitability and market share of the ultra-high-end infant formula milk powder division, and making progress in the adult nutrition and care products business in China, Australia and New Zealand's core markets.
Tomson By-Health forecasts net profit in the first quarter to fall by 20% to 40%
On April 1, By-Health released its performance forecast for the first quarter of 2024. The forecast net profit was 618 million yuan to 824 million yuan, down 20% to 40% from the same period last year, and the non-net profit after deduction fell in the range of 598 million yuan to 814 million yuan, down 18.2% to 39.91% from the same period last year.
The decline was mainly due to the high base in the same period last year. In the context of the ebb of the epidemic in 2023, the demand of the VDS industry exploded, and the company's net profit increased by 55% in the first quarter of last year, raising the base.
According to the 2023 performance report released by Tomson By-Health on February 20, Tomson By-Health will achieve a total operating income of 9.407 billion yuan in 2023, a year-on-year increase of 19.66%, a net profit of 1.746 billion yuan, a year-on-year increase of 26%, and a basic earnings per share of 1.03 yuan. Also due to the high base of previous years, in the annual report, Tomson By-Health gave a single-digit growth guidance for the annual growth rate in 2024.
Danone has had a good start to its 24 years and is moving forward steadily
On April 18, Danone announced its financial results for the first quarter of 2024, driven by the growth of all categories, the company achieved sales revenue of 6.789 billion euros in the first quarter, a year-on-year increase of 4.1%. All businesses in the Chinese market continued to grow.
According to the financial report, in the first quarter of 2024, Danone achieved sales revenue of 840 million euros in China, North Asia and Oceania, a year-on-year increase of 8.9%. Volume and mix contributed 6.9 percent of the growth, while price factors contributed 2 percent. In the Chinese market, the specialty nutrition business continued to maintain a competitive development trend, and Pulse started with double-digit high growth.
Antoine de Saint-Affrique, CEO of Danone, said: "We have made a good start to 2024, achieved high-quality growth again, and are well on our way to revitalizing Danone's strategy.
Looking ahead, Danone expects sales revenue to grow by 3% to 5% year-on-year in 2024.
The traditional Chinese medicine health business accounts for nearly 70% of Kangenbei's revenue
On April 19, Kangenbei released its 2023 annual report, with operating income of 6.733 billion yuan, a year-on-year increase of 12.20%, net profit attributable to shareholders of listed companies of 592 million yuan, a year-on-year increase of 65.19%, and net profit attributable to shareholders of listed companies of 554 million yuan, a year-on-year increase of 14.60%.
During the reporting period, the revenue of Kangenbei's traditional Chinese medicine health business was 4.544 billion yuan, an increase of 16.13% over the previous year, accounting for 67.49% of the company's total revenue, an increase of 2.28 percentage points over the previous year.
It is reported that in 2023, Kangenbei will sell 17 varieties of more than 100 million yuan, an increase of 2 from the previous year. The total sales revenue of products with a scale of more than 100 million yuan was 4.619 billion yuan, a year-on-year increase of 12.93%, accounting for 68.6% of the company's total revenue.
Lotus Health's performance continued to soar
On April 8, Lotus Health disclosed its first-quarter performance forecast. It is estimated that in the first quarter of 2024, the net profit attributable to the parent company will be 45 million yuan to 50 million yuan, a year-on-year increase of 114.42% to 138.24%, and the non-net profit will be 44.4 million yuan to 49.4 million yuan, a year-on-year increase of 109.92% to 133.56%.
On the same day, Lotus Health released its 2023 annual performance report. In 2023, Lotus Health achieved a total operating income of 2.101 billion yuan, a year-on-year increase of 24.23%, and a net profit attributable to the parent company of 128 million yuan, a year-on-year increase of 176.43%.
Lotus Health said in the financial report that the company continued to optimize the layout of the marketing network, strengthen marketing and sales, and achieved rapid growth in sales revenue. In addition, an effective procurement program has achieved a significant reduction in the procurement cost of major raw materials. Through the implementation of the equity incentive plan, the development vitality has been further released, and the turnover efficiency of major operational links such as R&D, production, and logistics has been greatly improved. Lotus Health believes that the above factors have jointly contributed to the company's performance to achieve substantial growth. As for the expected increase in performance in the first quarter of 2024, it is mainly due to the company's "brand revival strategy", strengthening brand publicity and sales promotion, and implementing measures to reduce costs and increase efficiency.
Xianle Health achieved excellent results in the first quarter
Xianle Health released a first-quarter results announcement on the evening of April 21, saying that the revenue in the first quarter of 2024 will be about 952 million yuan, an increase of 35.51% year-on-year, the net profit attributable to shareholders of listed companies will be about 63.03 million yuan, an increase of 114.39% year-on-year, and the basic earnings per share will be 0.3472 yuan, an increase of 113.14% year-on-year.
On April 22, Xianle Health announced its 2023 annual financial report. In 2023, the total operating revenue will be 3.582 billion yuan, a year-on-year increase of 41.87%, and the total profit will reach 281 million yuan, a year-on-year increase of 32.39%. Among them, the sales revenue of domestic business reached 1.851 billion yuan, a year-on-year increase of 24.11%. The sales revenue of overseas business reached 1.731 billion yuan, a year-on-year increase of 70.4%.
It can be seen from the financial report that the revenue of the three major dosage forms of soft capsules, nutritional gummies, and beverages is on the rise. Among them, the revenue of soft capsule dosage form reached 1.527 billion yuan, a year-on-year increase of 54%. The revenue of nutritional gummy dosage form reached 740 million yuan, a year-on-year increase of 24.81%. Beverage revenue reached 422 million yuan, a year-on-year increase of 24.66%.